Axcan unchanged at neutral by Merrill

Merrill Lynch analyst Hari Sambasivam kept Axcan Pharma Inc. at its neutral rating. Merrill's estimates for the first quarter include total product revenues of $62.5 million, compared to $61.6 million in the first quarter of 2005. The analyst increased its 2006 earnings per share to $0.62 from $0.56, with consensus at $0.64. Shares of the Mont-Saint-Hilaire, Quebec, pharmaceutical company were down 13 cents, or 0.71%, at $18.19 on volume of 674,047 shares versus the three-month running average of 329,595 shares. (Nasdaq: AXCA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.